Log in to save to my catalogue

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2493136720

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

About this item

Full title

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2021-02, Vol.384 (8), p.705-716

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Autologous T cells engineered to express a chimeric antigen receptor specific for the B-cell maturation antigen produced responses in the majority of patients with refractory and resistant myeloma, including deep molecular responses in 26% of treated patients. High-grade hematologic toxic effects and cytokine release syndrome were common.

Alternative Titles

Full title

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2493136720

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2493136720

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2024850

How to access this item